Prospective study of serum adiponectin and incident metabolic syndrome: The ARIRANG study

Jang Young Kim, Songvogue Ahn, JinHa Yoon, Sangbaek Koh, Junghan Yoon, Byungsu Yoo, Seunghwan Lee, Jong Ku Park, Kyung Hoon Choe, Eliseo Guallar

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

OBJECTIVE - Increased adiponectin levels may play a protective role in the development of metabolic abnormalities, but prospective studies of the predictive value of serum adiponectin to identify individuals at high risk of new-onset metabolic syndrome are lacking. We investigated whether serum adiponectin predicts incident cases of the metabolic syndrome in a populationbased longitudinal study. RESEARCH DESIGN ANDMETHODS - A prospective cohort study was conducted of 2,044 adults (831 men and 1,213 women) aged 40-70 years without metabolic syndrome examined in 2005-2008 (baseline) and 2008 - 2011 (follow-up). Baseline serum adiponectin concentrations were measured by radioimmunoassay. RESULTS - During an average of 2.6 years of follow-up, 153 men (18.4%) and 199 women (16.4%) developed metabolic syndrome. In multivariable-adjusted models, the odds ratio for incident metabolic syndrome comparing the highest with the lowest quartiles of adiponectin levels was 0.25 (95% CI 0.14-0.47) in men and 0.45 (0.28-0.74) in women. While serum adiponectin did not improve the area under the ROC curve for predicting new-onset metabolic syndrome based on information from metabolic syndrome components, the net reclassification improvement and the integrated discrimination improvement of prediction models including adiponectin were significantly higher compared with those of models not including adiponectin among men, with a signi ficant difference between men and women (P = 0.001). CONCLUSIONS - Increased adiponectin is an independent protective factor for incident metabolic syndrome in men and women, and it may have a clinical role in predicting new-onset metabolic syndrome among men.

Original languageEnglish
Pages (from-to)1547-1553
Number of pages7
JournalDiabetes Care
Volume36
Issue number6
DOIs
Publication statusPublished - 2013 Jun 1

Fingerprint

Adiponectin
Prospective Studies
Serum
ROC Curve
Area Under Curve
Radioimmunoassay
Longitudinal Studies
Cohort Studies
Research Design
Odds Ratio

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialised Nursing

Cite this

@article{7bf2679a490b487bb9c01f5d1b470b51,
title = "Prospective study of serum adiponectin and incident metabolic syndrome: The ARIRANG study",
abstract = "OBJECTIVE - Increased adiponectin levels may play a protective role in the development of metabolic abnormalities, but prospective studies of the predictive value of serum adiponectin to identify individuals at high risk of new-onset metabolic syndrome are lacking. We investigated whether serum adiponectin predicts incident cases of the metabolic syndrome in a populationbased longitudinal study. RESEARCH DESIGN ANDMETHODS - A prospective cohort study was conducted of 2,044 adults (831 men and 1,213 women) aged 40-70 years without metabolic syndrome examined in 2005-2008 (baseline) and 2008 - 2011 (follow-up). Baseline serum adiponectin concentrations were measured by radioimmunoassay. RESULTS - During an average of 2.6 years of follow-up, 153 men (18.4{\%}) and 199 women (16.4{\%}) developed metabolic syndrome. In multivariable-adjusted models, the odds ratio for incident metabolic syndrome comparing the highest with the lowest quartiles of adiponectin levels was 0.25 (95{\%} CI 0.14-0.47) in men and 0.45 (0.28-0.74) in women. While serum adiponectin did not improve the area under the ROC curve for predicting new-onset metabolic syndrome based on information from metabolic syndrome components, the net reclassification improvement and the integrated discrimination improvement of prediction models including adiponectin were significantly higher compared with those of models not including adiponectin among men, with a signi ficant difference between men and women (P = 0.001). CONCLUSIONS - Increased adiponectin is an independent protective factor for incident metabolic syndrome in men and women, and it may have a clinical role in predicting new-onset metabolic syndrome among men.",
author = "Kim, {Jang Young} and Songvogue Ahn and JinHa Yoon and Sangbaek Koh and Junghan Yoon and Byungsu Yoo and Seunghwan Lee and Park, {Jong Ku} and Choe, {Kyung Hoon} and Eliseo Guallar",
year = "2013",
month = "6",
day = "1",
doi = "10.2337/dc12-0223",
language = "English",
volume = "36",
pages = "1547--1553",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "6",

}

Prospective study of serum adiponectin and incident metabolic syndrome : The ARIRANG study. / Kim, Jang Young; Ahn, Songvogue; Yoon, JinHa; Koh, Sangbaek; Yoon, Junghan; Yoo, Byungsu; Lee, Seunghwan; Park, Jong Ku; Choe, Kyung Hoon; Guallar, Eliseo.

In: Diabetes Care, Vol. 36, No. 6, 01.06.2013, p. 1547-1553.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prospective study of serum adiponectin and incident metabolic syndrome

T2 - The ARIRANG study

AU - Kim, Jang Young

AU - Ahn, Songvogue

AU - Yoon, JinHa

AU - Koh, Sangbaek

AU - Yoon, Junghan

AU - Yoo, Byungsu

AU - Lee, Seunghwan

AU - Park, Jong Ku

AU - Choe, Kyung Hoon

AU - Guallar, Eliseo

PY - 2013/6/1

Y1 - 2013/6/1

N2 - OBJECTIVE - Increased adiponectin levels may play a protective role in the development of metabolic abnormalities, but prospective studies of the predictive value of serum adiponectin to identify individuals at high risk of new-onset metabolic syndrome are lacking. We investigated whether serum adiponectin predicts incident cases of the metabolic syndrome in a populationbased longitudinal study. RESEARCH DESIGN ANDMETHODS - A prospective cohort study was conducted of 2,044 adults (831 men and 1,213 women) aged 40-70 years without metabolic syndrome examined in 2005-2008 (baseline) and 2008 - 2011 (follow-up). Baseline serum adiponectin concentrations were measured by radioimmunoassay. RESULTS - During an average of 2.6 years of follow-up, 153 men (18.4%) and 199 women (16.4%) developed metabolic syndrome. In multivariable-adjusted models, the odds ratio for incident metabolic syndrome comparing the highest with the lowest quartiles of adiponectin levels was 0.25 (95% CI 0.14-0.47) in men and 0.45 (0.28-0.74) in women. While serum adiponectin did not improve the area under the ROC curve for predicting new-onset metabolic syndrome based on information from metabolic syndrome components, the net reclassification improvement and the integrated discrimination improvement of prediction models including adiponectin were significantly higher compared with those of models not including adiponectin among men, with a signi ficant difference between men and women (P = 0.001). CONCLUSIONS - Increased adiponectin is an independent protective factor for incident metabolic syndrome in men and women, and it may have a clinical role in predicting new-onset metabolic syndrome among men.

AB - OBJECTIVE - Increased adiponectin levels may play a protective role in the development of metabolic abnormalities, but prospective studies of the predictive value of serum adiponectin to identify individuals at high risk of new-onset metabolic syndrome are lacking. We investigated whether serum adiponectin predicts incident cases of the metabolic syndrome in a populationbased longitudinal study. RESEARCH DESIGN ANDMETHODS - A prospective cohort study was conducted of 2,044 adults (831 men and 1,213 women) aged 40-70 years without metabolic syndrome examined in 2005-2008 (baseline) and 2008 - 2011 (follow-up). Baseline serum adiponectin concentrations were measured by radioimmunoassay. RESULTS - During an average of 2.6 years of follow-up, 153 men (18.4%) and 199 women (16.4%) developed metabolic syndrome. In multivariable-adjusted models, the odds ratio for incident metabolic syndrome comparing the highest with the lowest quartiles of adiponectin levels was 0.25 (95% CI 0.14-0.47) in men and 0.45 (0.28-0.74) in women. While serum adiponectin did not improve the area under the ROC curve for predicting new-onset metabolic syndrome based on information from metabolic syndrome components, the net reclassification improvement and the integrated discrimination improvement of prediction models including adiponectin were significantly higher compared with those of models not including adiponectin among men, with a signi ficant difference between men and women (P = 0.001). CONCLUSIONS - Increased adiponectin is an independent protective factor for incident metabolic syndrome in men and women, and it may have a clinical role in predicting new-onset metabolic syndrome among men.

UR - http://www.scopus.com/inward/record.url?scp=84878227620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878227620&partnerID=8YFLogxK

U2 - 10.2337/dc12-0223

DO - 10.2337/dc12-0223

M3 - Article

C2 - 23275369

AN - SCOPUS:84878227620

VL - 36

SP - 1547

EP - 1553

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 6

ER -